I welcome the recent contributions published in this journal to the debate surrounding the appropriate monitoring of clozapine [1,2]. Although I believe that liberalization of the monitoring of clozapine use is justified, I also believe that liberalization may ironically diminish clozapine's efficacy in the real world. This is because some of clozapine's efficacy could be explained by the very uniqueness of the existing monitoring process, which represents a systemic inequity that needs to be redressed.
展开▼
